Point Mutation,Mutation Proportion (%),"The most common cancers to harbor a mutation in this gene (ROSETTA classification, % of all instances of this mutation)"
KRAS (Gly 12),1.5100969428611215,"Lung Adenocarcinoma (60.48%), Colorectal Adenocarcinoma (19.16%), Pancreatic Adenocarcinoma (5.99%)"
TP53 (Arg 273),1.0576867172907154,"Colorectal Adenocarcinoma (16.94%), Astrocytoma (10.38%), Mixed glioma (10.38%)"
TP53 (Tyr 220),0.6556696282395782,"Breast Carcinoma (13.21%), Head Neck Squamous Cell Carcinoma (11.32%), Ovarian Cancer (8.49%)"
FBXW7 (Arg 465),0.43484765982629303,"Colorectal Adenocarcinoma (47.37%), Gastric Adenocarcinoma (15.79%), Endometrial Cancer (14.04%)"
TP53 (Tyr 163),0.2811890590534554,"Lung Squamous Cell Carcinoma (15.91%), Head Neck Squamous Cell Carcinoma (13.64%), Ovarian Cancer (13.64%)"
FGFR3 (Ser 249),0.2588868759090533,"Urothelial Cancer (80.85%), Head Neck Squamous Cell Carcinoma (8.51%), Lung Squamous Cell Carcinoma (8.51%)"
IDH1 (Arg 132),0.23353074512131836,"Malignant Melanoma (22.97%), Astrocytoma (17.57%), Acute myeloid leukemia NOS (17.57%)"
TP53 (Tyr 236),0.17699264162958123,"Head Neck Squamous Cell Carcinoma (14.81%), Lung Squamous Cell Carcinoma (11.11%), Prostate Cancer (11.11%)"
RARS2 (Arg 6),0.176943434217948,"Urothelial Cancer (35%), Breast Carcinoma (25%), Lung Adenocarcinoma (15%)"
FBXW7 (Arg 505),0.17461625371915435,"Colorectal Adenocarcinoma (33.33%), Endometrial Cancer (29.63%), Malignant Melanoma (7.41%)"
SMAD4 (Arg 361),0.16666066811006883,"Colorectal Adenocarcinoma (45.83%), Pancreatic Adenocarcinoma (29.17%), Gastric Adenocarcinoma (16.67%)"
GNAS (Arg 201),0.1654178328786332,"Pancreatic Adenocarcinoma (35.29%), Colorectal Adenocarcinoma (17.65%), Hepatocellular Carcinoma (11.76%)"
KRAS (Gly 13),0.1646925576952763,"Lung Adenocarcinoma (57.14%), Endometrial Cancer (14.29%), Colorectal Adenocarcinoma (9.52%)"
AR (Trp 742),0.1621551036096891,"Prostate Cancer (100%), Seminoma (0%), Sarcoma (0%)"
SPOP (Phe 102),0.1621551036096891,"Prostate Cancer (100%), Seminoma (0%), Sarcoma (0%)"
TP53 (Tyr 234),0.15848228424580646,"Lung Squamous Cell Carcinoma (20.59%), Breast Carcinoma (11.76%), Urothelial Cancer (8.82%)"
TP53 (Arg 337),0.15308996644325676,"Head Neck Squamous Cell Carcinoma (18.18%), Breast Carcinoma (9.09%), Prostate Cancer (9.09%)"
ATM (Arg 337),0.15219803992512984,"Colorectal Adenocarcinoma (35%), Malignant Melanoma (10%), Gastric Adenocarcinoma (10%)"
TP53 (Tyr 205),0.1313931750684772,"Hepatocellular Carcinoma (15.38%), Lung Adenocarcinoma (15.38%), Esophageal Squamous Cell Carcinoma (11.54%)"
FOLH1 (Arg 281),0.12040778283422826,"Colorectal Adenocarcinoma (90%), Lung Adenocarcinoma (10%), Seminoma (0%)"
SPOP (Phe 133),0.10810340240645941,"Prostate Cancer (100%), Seminoma (0%), Sarcoma (0%)"
PPP6C (Arg 264),0.10540593696684558,"Malignant Melanoma (94.44%), Lung Squamous Cell Carcinoma (5.56%), Seminoma (0%)"
ARHGAP9 (Arg 66),0.10315344716721833,"Colorectal Adenocarcinoma (37.5%), Breast Carcinoma (25%), Prostate Cancer (12.5%)"
ISX (Arg 86),0.10190223868530594,"Malignant Melanoma (88.89%), Head Neck Squamous Cell Carcinoma (5.56%), Endometrial Cancer (5.56%)"
MDC1 (Gly 1558),0.0944382680874185,"Urothelial Cancer (66.67%), Malignant Melanoma (16.67%), Prostate Cancer (16.67%)"
